ArticleWorld journal of surgery2025
Comparison of Oncocytic and Follicular Carcinoma of the Thyroid Without Initial Distant Metastasis.
Article in World journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of Oncocytic and Follicular Carcinoma of the Thyroid Without Initial Distant Metastasis.World journal of surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOncocytic thyroid carcinoma (OTC) is recognized as a distinct entity of follicular thyroid carcinoma (FTC), and its prognosis has traditionally been considered poor. However, the available data on this topic remain limited and highly heterogeneous. The objective of this study was to investigate the clinicopathological features and prognosis of patients with OTC and compare them with those of patients with FTC.
methodsA retrospective comparative study of all patients who underwent total thyroidectomy for OTC or FTC in a high-volume endocrine surgery center between January 2005 and December 2021. Demographic and clinicopathological characteristics, complications, and recurrence rates were compared using univariate and multivariate regression analyses.
resultsIn total, 347 patients, 72% female, median age 48 years (35-61 years) were enrolled, including 123 with OTC and 224 with FTC. Patients were significantly older in the OTC group than in the FTC group (54.7 vs. 44.5 years, respectively, p = 0.001). With respect to other demographic, clinical, and pathological characteristics, no statistically significant differences were observed between the two groups. The median follow-up duration was 5.6 years (3.2-10.5 years). Eighteen patients (5.2%) experienced recurrence, including 7 (5.7%) in the OTC group and 11 (4.9%) in the FTC group. No difference in recurrence-free survival was observed between the OTC and FTC groups (p = 0.47). In multivariate analysis, histological type was not associated with the risk of recurrence.
conclusionPatients withOTC have the same recurrence rate as do patients with FTC . It does not appear justified to propose a different therapeutic management for this histological type, and a stepdown management could be proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.